Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars
Diagnostics company Guardant Health (NASDAQ: GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates. Is now the time to buy Guardant Health? Find out by accessing our full research report, it’s free.
How this was made
The 30-second read
Why it matters
The article frames the quarter as a revenue and guidance beat with an EPS miss, implying investors may reward growth while scrutinizing the pace of margin improvement and loss reduction.
Market read
Traders can use the disclosed revenue growth, full-year guidance midpoint, and adjusted EPS miss to reassess near-term expectations and volatility around profitability progress.
What to watch
Adjusted operating margin is still negative (-19.9% this quarter), so investors may re-rate the stock on cash burn and path to sustained profitability rather than top-line growth.
Background
Guardant Health develops liquid biopsy blood tests to detect and monitor cancer mutations from tumor DNA in the bloodstream.
Ticker impact
Guardant Health reported Q2 CY2026 revenue up 44.3% to $335M and guided full-year revenue to $1.35B at the midpoint, beating estimates.
Likely continued post-earnings momentum, with pullbacks possible if investors focus on the EPS miss and margin trajectory.
The article provides concrete results (revenue beat, guidance beat) plus a specific offset (adjusted EPS miss) and notes the stock jumped 6.8% to $162.68 immediately after results.
Market effects
Reinforces demand strength for liquid biopsy diagnostics, potentially supporting sentiment across oncology diagnostics peers.
Primarily US small/mid-cap healthcare sentiment, with limited direct regional spillover described.
No explicit global regulatory or competitive developments mentioned beyond company financial performance.
Counterpoint
The revenue beat may not translate into profitability soon, since adjusted EPS missed and margins remain negative.
Key entities
- companyGuardant Health
NASDAQ-listed liquid biopsy diagnostics company reporting Q2 CY2026 results and full-year revenue guidance.
